ThinkSabio

$ARWR

$59.75▲ +0.4% YTD

13 SEC 13D/G filings tracked · Last updated Nov 4, 2026

Filing History
News
ARWR ▲ +0.4% - Arrowhead Pharmaceuticals, Inc.
CP $59.75▲ +0.4%Nov 4, 2026 · ThinkSabio Blog

$ARWR - Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity…

News
ARWR ▲ +0.4% - Arrowhead Pharmaceuticals, Inc.
CP $59.75▲ +0.4%Nov 4, 2026 · ThinkSabio Blog

$ARWR Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity…

News
ARWR ▼ -0.1% - Arrowhead Pharmaceuticals, Inc.
CP $59.53▲ -0.1%Nov 3, 2026 · ThinkSabio Blog

$ARWR - Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results…

News
ARWR ▲ +2.0% - Arrowhead Pharmaceuticals, Inc.
CP $60.14▲ +2.0%Oct 27, 2026 · ThinkSabio Blog

$ARWR - Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Redu…

News
ARWR ▲ +0.7% - Arrowhead Pharmaceuticals, Inc.
CP $58.83▲ +0.7%Oct 15, 2026 · ThinkSabio Blog

$ARWR covg assumed with a Buy at UBS. PT $109…

News
ARWR ▲ +3.0% - Arrowhead Pharmaceuticals, Inc.
CP $59.90▲ +3.0%Oct 14, 2026 · ThinkSabio Blog

$ARWR - Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunte…

News
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.
CP $62.60▲ +1.8%Oct 7, 2026 · ThinkSabio Blog

$ARWR - Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia…

News
ARWR ▲ +1.8% - Arrowhead Pharmaceuticals, Inc.
CP $62.60▲ +1.8%Oct 7, 2026 · ThinkSabio Blog

$ARWR Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia…

News
ARWR ▼ -0.8% - Arrowhead Pharmaceuticals, Inc.
CP $84.71▲ -0.8%Sep 3, 2026 · ThinkSabio Blog

$ARWR - Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences…

News
ARWR ▼ -3.8% - Arrowhead Pharmaceuticals, Inc.
CP $85.24▲ -3.8%Aug 30, 2026 · ThinkSabio Blog

$ARWR - Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients w…

SEC 13D/G
ARWR - Arrowhead Pharmaceuticals, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks Simplified
$85.59▲ 26.20%Aug 14, 2026 · ThinkSabio Blog

$ARWR SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ARWR Arrowhead Pharmaceuticals, Inc. : $85.59 Sector: Healthcar…

SEC 13D/G
$ARWR SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks Simplified
$84.88▲ 25.15%Jul 31, 2026 · ThinkSabio Blog

$ARWR SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ARWR : $84.88 Sector: Healthcare | YTD: 🔼+ 25.15% The SEC discl…

SEC 13D/G
$ARWR SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks Simplified
$85.53▲ 26.11%Jul 27, 2026 · ThinkSabio Blog

$ARWR SEC 13D/G institutional ownership filing. Healthcare sector. SEC Filing Update: #ARWR : $85.53 Sector: Healthcare | YTD: 🔼+ 26.11% The SEC discl…